An attempt to abrogate the placebo response does not seem to have gone as planned.
As the company is punished for its failure to diversify, could it be forced into making an acquisition?
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.